Abstracts Archive - Page 1047 of 2607 - ACR Meeting Abstracts

Abstract Number: 1603 • 2019 ACR/ARP Annual Meeting
Stroke Clusters in SLE by Lupus Autoantibodies
Michelle Petri¹ and Daniel Goldman ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Stroke is the most common arterial thrombotic event in SLE. It is known to be associated with antiphospholipid antibodies, but clinicians have additional concern…
Abstract Number: 1604 • 2019 ACR/ARP Annual Meeting
The Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹, Erik Barr ² and Laurence Magder ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in systemic lupus erythematosus (SLE). Yet, the "traditional" cardiovascular risk equations (such…
Abstract Number: 1605 • 2019 ACR/ARP Annual Meeting
Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Homocysteinemia is present 8-15% of patients with SLE and is associated with increased risk of atherosclerosis, arterial thrombosis and stroke in SLE patients. Recently,…
Abstract Number: 1606 • 2019 ACR/ARP Annual Meeting
Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Smoking and African- American ethnicity are risk factors for systemic lupus erythematosus (SLE). Smoking has been associated with increased prevalence of SLE, increased disease…
Abstract Number: 1607 • 2019 ACR/ARP Annual Meeting
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors…
Abstract Number: 1608 • 2019 ACR/ARP Annual Meeting
Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis
Chiu Sum Chu ¹, Chi Chiu Mok², Ling Yin Ho ¹ and Chi Hung To ¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To study the effect of the metabolic syndrome (MetS) on renal function decline in four rheumatic diseases.Methods: Consecutive patients who fulfilled the ACR/SLICC criteria…
Abstract Number: 1609 • 2019 ACR/ARP Annual Meeting
Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis
Chi Chiu Mok¹, Chi Shan Sin ², Kai Ching Hau ² and Tse Hoi Kwan ², ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the organ damage free survival and its predictive factors in patients with active LN.Methods: Consecutive patients who fulfilled ≥4 ACR/SLICC criteria for…
Abstract Number: 1610 • 2019 ACR/ARP Annual Meeting
Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index
Alexandra Legge¹, Susan Kirkland ¹, Kenneth Rockwood ¹, Pantelis Andreou ¹, Sang-Cheol Bae ², Caroline Gordon ³, Juanita Romero-Diaz ⁴, Jorge Sanchez-Guerrero ⁵, Daniel J Wallace ⁶, Sasha Bernatsky ⁷, Ann E Clarke ⁸, Joan Merrill ⁹, Ellen M Ginzler ¹⁰, Paul Fortin ¹¹, Dafna Gladman ¹², Murray Urowitz ¹³, Ian Bruce ¹⁴, David A Isenberg ¹⁵, Anisur Rahman ¹⁶, Graciela Alarcón ¹⁷, Michelle Petri ¹⁸, Munther A Khamashta ¹⁹, MA Dooley ²⁰, Rosalind Ramsey-Goldman ²¹, Susan Manzi ²², Kristjan Steinsson ²³, Asad A Zoma ²⁴, Cynthia Aranow ²⁵, Meggan Mackay ²⁶, Guillermo Ruiz-Irastorza ²⁷, S Sam Lim ²⁸, Murat Inanc ²⁹, Ronald F Van Vollenhoven ³⁰, Andreas Jönsen ³¹, Ola Nived ³¹, Manuel Ramos-Casals ³², Diane Kamen ³³, Kenneth C Kalunian ³⁴, Soren Jacobsen ³⁵, Christine Peschken ³⁶, Anca Askanase ³⁷ and John G Hanly ¹, ¹Dalhousie University, Halifax, NS, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Birmingham, Birmingham, United Kingdom, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁵Toronto Western Hospital, Toronto, ON, Canada, ⁶Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Oklahoma Medical Research Foundation, Oklahoma City, ¹⁰State University of New York Downstate Medical Center, Brooklyn, NY, ¹¹Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁵Centre for Rheumatology, London, United Kingdom, ¹⁶University College London, London, United Kingdom, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹King's College London School of Medicine, London, United Kingdom, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburg, PA, ²³Landspitali, University Hospital, Reykjavik, Iceland, ²⁴University of Glasgow, East Kilbride, United Kingdom, ²⁵Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Feinstein Institute for Medical Research, New York, ²⁷Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁰Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³¹Lund University, Lund, Sweden, ³²Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴UC San Diego School of Medicine, LaJolla, CA, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶University of Manitoba, Winnipeg, Canada, ³⁷Columbia University Medical Center, New York, NY
Background/Purpose: We previously constructed a frailty index (FI) as a measure of susceptibility to adverse outcomes among patients with systemic lupus erythematosus (SLE). In this…
Abstract Number: 1611 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?
Jennifer Lofland¹, Eric Wan ², Pamela Berry ³ and Chetan Karyekar ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Johns Hopkins Bloomberg School of Public Health, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Global Services, LLC, Horsham, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that causes connective tissue inflammation and can result in multiple organ damage. Registries may be…
Abstract Number: 1612 • 2019 ACR/ARP Annual Meeting
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough ¹, Shane McKie ², Benjamin Parker ¹, Alan Jackson ³, Philip Pemberton ⁴, Rebecca Elliott ⁵ and Ian Bruce⁶, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, United Kingdom, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University NHS Foundation Trust, Manchester, ⁵Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is a common symptom in systemic lupus erythematosus (SLE), that significantly affects quality of life but there are limited treatment options…
Abstract Number: 1613 • 2019 ACR/ARP Annual Meeting
LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis
Ji-Hyoun Kang¹, Seong-Eun Choi ¹, Haimuzi Xu ¹, Dong-Jin Park ¹ and Shin-Seok Lee ², ¹Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ²Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: There are few data on the effect of dyslipidemia in patients with lupus nephritis (LN). Thus, we investigated the effect of low-density lipoprotein-cholesterol (LDL-C)…
Abstract Number: 1614 • 2019 ACR/ARP Annual Meeting
Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Gabriela Garcia-Guevara¹, Francisco Treviño-Tello ², Christopher Cabib ¹, Irazú Contreras-Yáñez ³, Erwin Chiquete ⁴, Ariadna Díaz-Mora ¹, Yuliana Fernandez-Nicoli ⁴, Julio Macias-Gallardo ⁵, Juan José Gómez-Piña ⁴, Ivonne Sandoval-Flores ⁴ and Hilda Fragoso-Loyo ⁶, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: The prevalence of peripheral neurological manifestations in Systemic Lupus Erythematosus (SLE) ranges between 1.5% and 27% and are a major cause of morbidity.To determine…
Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Yoshiyuki Arinuma ¹, Yasuhiro Hasegawa ¹, Takumi Muramatsu¹, Yu Matsueda ¹ and Kunihiro Yamaoka ¹, ¹Department of Rheumatology and Infectious Diseaes, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…
Abstract Number: 1616 • 2019 ACR/ARP Annual Meeting
Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim is to investigate the association between the…
Abstract Number: 1617 • 2019 ACR/ARP Annual Meeting
Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus
Yevgeniya Gartshteyn¹, Adam Mor ², Laura Geraldino ², Teja Kapoor ², Tommy Chen ², Thierry Dervieux ³ and Anca Askanase ⁴, ¹Columbia University School of Medicine, Glen Rock, NJ, ²Columbia University School of Medicine, New York, NY, ³Exagen, Vista, CA, ⁴Columbia University, New York
Background/Purpose: Cell-bound complement activation products (CB-CAPs), including platelet bound C4d (PC4d), are sensitive markers for diagnosis and evaluation of lupus activity. Presence of PC4d is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].